CUP.F Chugai Pharmaceutical Co. Ltd

Healthcare Pharmaceuticals Frankfurt Exchange
40.48 EUR
Close of Nov 11, 2026
33.52 55.73
Market cap
EUR 66.6B
P/E
24.2x
P/B
5.58x
ROE
24.0%
Dividend yield
1.87%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is CUP.F undervalued?

Graham number
Price40.48
Graham value16.52
Premium145.1%

CUP.F trades 145.1% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Chugai Pharmaceutical Co. Ltd fundamental analysis

No fundamental analysis for Chugai Pharmaceutical Co. Ltd yet.

Chugai Pharmaceutical Co. Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Chugai Pharmaceutical Co. Ltd

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding human…

Full company profile